

# Kazuya Shimoda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3619363/publications.pdf>

Version: 2024-02-01

131  
papers

4,547  
citations

257450

24  
h-index

106344

65  
g-index

136  
all docs

136  
docs citations

136  
times ranked

6731  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy. <i>Case Reports in Gastroenterology</i> , 2022, 15, 838-845.	0.6	3
2	Whole-genome landscape of adult T-cell leukemia/lymphoma. <i>Blood</i> , 2022, 139, 967-982.	1.4	44
3	Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. <i>International Journal of Hematology</i> , 2022, 115, 208-221.	1.6	7
4	Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice. <i>International Journal of Hematology</i> , 2022, 115, 198-207.	1.6	3
5	Inhibition of adult T cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis. <i>Cancer Science</i> , 2022, 113, 1406-1416.	3.9	5
6	Secondary Skin Cancer in a Case with Long-term Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Internal Medicine</i> , 2022, , .	0.7	1
7	Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 256, 119-125.	1.2	1
8	Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma. <i>Viruses</i> , 2022, 14, 710.	3.3	2
9	Momelotinib reduces transfusion requirements in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2022, 63, 1718-1722.	1.3	8
10	Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. <i>International Journal of Hematology</i> , 2022, 116, 215-227.	1.6	8
11	Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma. <i>Experimental Hematology</i> , 2022, 111, 41-49.	0.4	0
12	Longitudinal changes in an autonomously functioning thyroid nodule with coexisting follicular thyroid carcinoma over 14 years. <i>Oxford Medical Case Reports</i> , 2022, 2022, omac041.	0.4	1
13	Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T cell leukemia/lymphoma: Phase IIb results. <i>Cancer Science</i> , 2022, 113, 2778-2787.	3.9	16
14	Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. <i>International Journal of Hematology</i> , 2022, 116, 696-711.	1.6	1
15	Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. <i>Haematologica</i> , 2021, 106, 532-542.	3.5	9
16	Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. <i>Leukemia</i> , 2021, 35, 454-467.	7.2	27
17	Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T cell leukemia/lymphoma. <i>European Journal of Haematology</i> , 2021, 106, 398-407.	2.2	6
18	Three cases of late-onset anthracycline-related cardiomyopathy due to chemotherapies for hematological malignancy. <i>Journal of Echocardiography</i> , 2021, 19, 45-52.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion. <i>Pharmaceuticals</i> , 2021, 14, 353.	3.8	3
20	Ursodeoxycholic acid markedly promotes the absorption of microemulsion $\alpha$ -formulated cyclosporine A: A case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, , .	1.5	1
21	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. <i>Blood Cancer Discovery</i> , 2021, 2, 450-467.	5.0	10
22	Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy. <i>Anticancer Research</i> , 2021, 41, 4127-4131.	1.1	0
23	Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF- $\kappa$ B signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells. <i>PLoS ONE</i> , 2021, 16, e0256320.	2.5	13
24	Fibrocytes in primary myelofibrosis. <i>Oncotarget</i> , 2021, 12, 2101-2103.	1.8	0
25	Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis. <i>Leukemia</i> , 2021, , .	7.2	4
26	Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan. <i>Journal of Clinical Medicine</i> , 2021, 10, 105.	2.4	5
27	Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. <i>Nature Communications</i> , 2021, 12, 6177.	12.8	30
28	Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 1585-1592.	1.4	12
29	Single Rectal Neuroendocrine Tumor Associated with Multiple Endocrine Cell Micronests. <i>Internal Medicine</i> , 2020, 59, 619-623.	0.7	2
30	TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. <i>BMC Cancer</i> , 2020, 20, 5.	2.6	16
31	Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2 <sup>low</sup> ATL and various cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118615.	4.1	11
32	JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). <i>International Journal of Hematology</i> , 2020, 112, 268-291.	1.6	21
33	Clinical characteristics of adult T-cell leukemia/lymphoma infiltration in the gastrointestinal tract. <i>BMC Gastroenterology</i> , 2020, 20, 298.	2.0	0
34	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020, 136, 698-714.	1.4	28
35	The mechanism of Tyk2 deficiency-induced immunosuppression in mice involves robust IL-10 production in macrophages. <i>Cytokine</i> , 2020, 130, 155077.	3.2	9
36	Abstract 12873: Clonal Hematopoiesis With JAK2V617F Promotes Pulmonary Hypertension Through ALK1. <i>Circulation</i> , 2020, 142, .	1.6	1

#	ARTICLE	IF	CITATIONS
37	JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review. <i>Leukemia Research Reports</i> , 2020, 13, 100194.	0.4	0
38	Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 103-107.	0.8	1
39	Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms. <i>Blood</i> , 2020, 136, 106-118.	1.4	10
40	<i>&lt;i&gt;CARD11&lt;/i&gt;</i> Mutation Induces Oligoclonal Expansion of T-Cells, and Accelerates ATL Development in Combination with HBZ. <i>Blood</i> , 2020, 136, 17-18.	1.4	1
41	Dissecting Multicellular Ecosystems of HTLV-1 Infection and ATL By Multi-Omics Single Cell Analysis. <i>Blood</i> , 2020, 136, 18-18.	1.4	0
42	Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas. <i>Blood</i> , 2020, 136, 3-4.	1.4	1
43	The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply. <i>Blood</i> , 2020, 136, 24-25.	1.4	1
44	Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2020, 136, 29-30.	1.4	0
45	Essential thrombocytosis attributed to JAK2-T875N germline mutation. <i>International Journal of Hematology</i> , 2019, 110, 584-590.	1.6	11
46	The regulation of NDRG2 expression during ATLL development after HTLV-1 infection. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2633-2646.	3.8	7
47	Acute Liver Failure Due to Severe Hepatic Metastasis of Small-cell Lung Cancer Producing Adrenocorticotrophic Hormone Complicating Ectopic Cushing Syndrome. <i>Internal Medicine</i> , 2019, 58, 2977-2982.	0.7	2
48	Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. <i>Blood</i> , 2019, 133, 1619-1629.	1.4	21
49	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. <i>Leukemia</i> , 2019, 33, 2867-2883.	7.2	148
50	Degradation of p47 by autophagy contributes to CADM1 overexpression in ATLL cells through the activation of NF- $\kappa$ B. <i>Scientific Reports</i> , 2019, 9, 3491.	3.3	14
51	Monocyte-derived fibrocytes elimination had little contribution on liver fibrosis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 348-353.	1.3	3
52	Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis. <i>Blood Cancer Journal</i> , 2019, 9, 42.	6.2	15
53	Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. <i>Blood</i> , 2019, 134, 1663-1663.	1.4	5
54	$\text{IL-17}\beta$ Expression Requires Both TYK2/STAT3 Activity and IL-17-Regulated mRNA Stabilization. <i>ImmunoHorizons</i> , 2019, 3, 172-185.	1.8	17

#	ARTICLE	IF	CITATIONS
55	Clinical Features and Treatment Outcomes of Hematopoietic Stem Cell Transplantation During 2006-2016 at a Single Institution in Miyazaki Prefecture. <i>Journal of Hematopoietic Cell Transplantation</i> , 2019, 8, 122-134.	0.1	0
56	The Role of Calreticulin in Normal Hematopoiesis and Neoplastic Hematopoiesis of Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 309-309.	1.4	0
57	Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. <i>International Journal of Hematology</i> , 2018, 107, 681-688.	1.6	13
58	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2018, 131, 215-225.	1.4	124
59	Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. <i>International Journal of Hematology</i> , 2018, 107, 92-97.	1.6	5
60	Clinical effect of rituximab as early administration for refractory thrombotic thrombocytopenic purpura associated with connective tissue diseases. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 59-67.	0.7	1
61	Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. <i>Current Medical Research and Opinion</i> , 2018, 34, 531-537.	1.9	5
62	Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia. <i>International Journal of Hematology</i> , 2018, 108, 411-415.	1.6	14
63	Outcome of allogeneic hematopoietic cell transplantation in patients with adult <sc>T</sc>-cell leukemia. <i>Hematological Oncology</i> , 2018, 36, 651-655.	1.7	7
64	Haploinsufficiency of CALR Confers Hematopoietic Stem Cells (HSCs) with a Clonal Advantage over Wild-Type Cells, and, in Setting of Myeloproliferative Neoplasms, Compensates for the Functions of HSCs Impaired By the Calr Mutation. <i>Blood</i> , 2018, 132, 97-97.	1.4	2
65	Insufficiency of Non-Canonical PRC1 Complex Cooperates with an Activating JAK2 Mutation in the Pathogenesis of Myelofibrosis. <i>Blood</i> , 2018, 132, 100-100.	1.4	0
66	TET2 Mutation Associated with Organ Infiltrations in ATLL. <i>Blood</i> , 2018, 132, 1345-1345.	1.4	0
67	Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice. <i>European Journal of Haematology</i> , 2017, 98, 501-507.	2.2	14
68	Impact of TET2 deficiency on iron metabolism in erythroblasts. <i>Experimental Hematology</i> , 2017, 49, 56-67.e5.	0.4	11
69	Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. <i>Biochemical and Biophysical Research Communications</i> , 2017, 485, 144-151.	2.1	26
70	A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). <i>American Journal of Hematology</i> , 2017, 92, 1324-1332.	4.1	9
71	Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. <i>International Journal of Hematology</i> , 2017, 105, 309-317.	1.6	13
72	Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. <i>International Journal of Hematology</i> , 2017, 105, 59-69.	1.6	13

#	ARTICLE	IF	CITATIONS
73	Sequential Organ Failure Assessment (SOFA) score as a prognostic factor for disseminated intravascular coagulation patients with infectious disease treated with recombinant human soluble thrombomodulin (rhTM) in clinical practice. Japanese Journal of Transfusion and Cell Therapy, 2017, 63, 763-779.	0.2	3
74	Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Advances, 2017, 1, 1001-1015.	5.2	16
75	Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With <i>JAK2</i>- or <i>CALR</i>-Mutations. Annals of Laboratory Medicine, 2017, 37, 159-161.	2.5	1
76	Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm. Anticancer Research, 2017, 37, 3841-3847.	1.1	1
77	Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. World Journal of Hepatology, 2017, 9, 1340-1345.	2.0	8
78	7. Current Treatment for Leukemia. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 546-551.	0.0	0
79	Mutant calreticulin causes essential thrombocythemia. Oncotarget, 2017, 8, 88251-88252.	1.8	0
80	Surrounding Gastric Mucosa Findings Facilitate Diagnosis of Gastric Neoplasm as Gastric Adenoma or Early Gastric Cancer. Gastroenterology Research and Practice, 2016, 2016, 1-5.	1.5	2
81	Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014). Internal Medicine, 2016, 55, 1439-1445.	0.7	10
82	Aberrant PD-L1 expression through 3' UTR disruption in multiple cancers. Nature, 2016, 534, 402-406.	27.8	536
83	Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood, 2016, 127, 596-604.	1.4	98
84	The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. Journal of Experimental Medicine, 2016, 213, 1459-1477.	8.5	86
85	Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients. International Journal of Hematology, 2016, 103, 423-428.	1.6	8
86	Ezh2 regulates the Lin28/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells. Experimental Hematology, 2016, 44, 282-296.e3.	0.4	33
87	Mogamulizumab for ATLL in Clinical Practice. Blood, 2016, 128, 2998-2998.	1.4	1
88	Physiological Expression of Calr Mutant Increases Cell Growth and Cytokine Independency in Human Cell Lines Expressing Mpl, and Develops Essential Thrombocythemia in Mice. Blood, 2016, 128, 954-954.	1.4	0
89	Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood, 2015, 125, 304-315.	1.4	67
90	Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway. Molecular Nutrition and Food Research, 2015, 59, 2143-2154.	3.3	23

#	ARTICLE	IF	CITATIONS
91	Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms. <i>Genomics Data</i> , 2015, 4, 102-108.	1.3	4
92	Integrated molecular analysis of adult T cell leukemia/lymphoma. <i>Nature Genetics</i> , 2015, 47, 1304-1315.	21.4	659
93	Reduced Tyk2 gene expression in $\hat{I}^2$ -cells due to natural mutation determines susceptibility to virus-induced diabetes. <i>Nature Communications</i> , 2015, 6, 6748.	12.8	45
94	Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2015, 126, 3882-3882.	1.4	0
95	Analysis of DNA Methylation in Bowel Lavage Fluid for Detection of Colorectal Cancer. <i>Cancer Prevention Research</i> , 2014, 7, 1002-1010.	1.5	38
96	Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. <i>Nature Communications</i> , 2014, 5, 3393.	12.8	134
97	NS-018, a Selective JAK2V617F Inhibitor, Improves JAK2V617F-Induced Murine Myelofibrosis Without Decreasing The Erythrocyte Or Platelet Count. <i>Blood</i> , 2013, 122, 3847-3847.	1.4	2
98	$\hat{I}^2$ SMA+ Macrophages Skewed From Hematopoietic Stem Cells By Vitamin D3 Initiate Myelofibrosis and Subsequent Osteosclerosis. <i>Blood</i> , 2013, 122, 340-340.	1.4	0
99	Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan. <i>International Journal of Hematology</i> , 2012, 96, 342-349.	1.6	7
100	CD3 and EBER double positive cells in bone marrow are a diagnostic aid for EBV-positive T-cell lymphoproliferative disorders of childhood. <i>International Cancer Conference Journal</i> , 2012, 1, 33-36.	0.5	0
101	Long-Term Cell Autonomous Effect of Tet2 Loss in Hematopoietic Cells in Mice.. <i>Blood</i> , 2012, 120, 2416-2416.	1.4	0
102	TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation. <i>Blood</i> , 2011, 118, 2471-2471.	1.4	0
103	NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant. <i>Blood</i> , 2010, 116, 4106-4106.	1.4	5
104	Preferential Inhibition of An Activated Form of Janus Kinase 2 (JAK2) by a Novel JAK2 Inhibitor, NS-018. <i>Blood</i> , 2010, 116, 4107-4107.	1.4	4
105	Potentiated Activation of VLA-4 and VLA-5 Accelerates Proplatelet-Like Formation In Megakaryocytes.. <i>Blood</i> , 2010, 116, 2585-2585.	1.4	0
106	The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. <i>European Journal of Haematology</i> , 2009, 83, 328-333.	2.2	27
107	Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model.. <i>Blood</i> , 2009, 114, 3897-3897.	1.4	3
108	JAK2V617F Mutation Selectively Exerts the STAT3 Pathway for Enhancing a Neutrophil Activation Marker.. <i>Blood</i> , 2009, 114, 1901-1901.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Absence of Somatically Acquired JAK1 Mutations in Adult T-Cell Leukemia/Lymphoma.. Blood, 2009, 114, 1921-1921.	1.4	0
110	High serum levels of granulocyte-macrophage colony-stimulating factor in patients with liver cirrhosis and granulocytopenia. International Journal of Laboratory Hematology, 2008, 17, 61-63.	0.2	18
111	Elevated Leukocyte Alkaline Phosphatase Scores Induced by Jak2 V617F Mutation. Blood, 2008, 112, 5244-5244.	1.4	0
112	Regulation of p27 by S-Phase Kinase- Associated Protein 2 Is Associated with Aggressiveness in Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2008, 112, 3760-3760.	1.4	0
113	Analysis of Idiopathic Myelofibrosis Initiating Cell in NOD/SCID/IL2rgKO Mice. Blood, 2008, 112, 3715-3715.	1.4	0
114	The Effect of Anabolic Steroids on Anemia in Myelofibrosis with Myeloid Metaplasia: Retrospective Analysis of 39 Patients in Japan. International Journal of Hematology, 2007, 85, 338-343.	1.6	36
115	Transplantation of Primary Human CD34+CD38 - Hematopoietic Stem Cells Recapitulates Idiopathic Myelofibrosis in the NOD/scid/IL2rgKO Mice.. Blood, 2007, 110, 260-260.	1.4	0
116	Treatment of Idiopathic Myelofibrosis Employing siRNA for Heat Shock Protein 47 (siRNA/HSP47) Encapsulated in Liposomes.. Blood, 2007, 110, 4646-4646.	1.4	0
117	Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leukemia Research, 2005, 29, 761-769.	0.8	53
118	Cutting Edge: Tyk2 Is Required for the Induction and Nuclear Translocation of Daxx Which Regulates IFN- $\gamma$ -Induced Suppression of B Lymphocyte Formation. Journal of Immunology, 2002, 169, 4707-4711.	0.8	54
119	Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood, 2002, 99, 2094-2099.	1.4	63
120	ticlopidine-Associated Thrombotic Thrombocytopenic Purpura With an IgG-Type Inhibitor to von Willebrand Factor-Cleaving Protease Activity. International Journal of Hematology, 2001, 74, 347-351.	1.6	21
121	A Common Genetic Polymorphism (46 C to T Substitution) in the 5' Untranslated Region of the Coagulation Factor XII Gene Is Associated With Low Translation Efficiency and Decrease in Plasma Factor XII Level. Blood, 1998, 91, 2010-2014.	1.4	187
122	Analysis of the granulocyte colony-stimulating factor receptor gene structure using PCR-SSCP in myeloid leukemia and myelodysplastic syndrome. European Journal of Haematology, 1998, 60, 197-201.	2.2	12
123	Jaks and stats in cytokine signaling. Stem Cells, 1997, 15, 105-112.	3.2	100
124	Jak1 Plays an Essential Role for Receptor Phosphorylation and Stat Activation in Response to Granulocyte Colony-Stimulating Factor. Blood, 1997, 90, 597-604.	1.4	7
125	Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene. Nature, 1996, 380, 630-633.	27.8	1,223
126	The c-kit Molecule and the Surface Immunophenotype of Human Acute Leukemia. Leukemia and Lymphoma, 1994, 14, 421-428.	1.3	18



#	ARTICLE	IF	CITATIONS
127	Analysis of acute myeloid leukemia cells by flow cytometry, introducing a new light-scattering classification. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 553-557.	2.5	8
128	Cytokine production by peripheral blood monocytes and T cells during haemopoietic recovery after intensive chemotherapy. <i>British Journal of Haematology</i> , 1993, 83, 21-27.	2.5	41
129	CD7-positive acute myeloid leukemia: further evidence of cellular immaturity. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 386-388.	2.5	8
130	Constitutive production of granulocyte colony-stimulating factor and interleukin-6 by a human lung cancer cell line, KSNY: Gene amplification and increased mRNA stability. <i>European Journal of Haematology</i> , 1991, 47, 128-133.	2.2	43
131	Serum Granulocyte Colony-Stimulating Factor Levels in Chronic Neutropenia of Infancy. <i>Pediatric Hematology and Oncology</i> , 1990, 7, 377-381.	0.8	10